In order to fully implement the spirit of the Fifth Plenary Session of the 19th Central Committee of the Party and the Central Economic Work Conference, make high-quality development a good start for the "14th Five-Year Plan", strengthen the deep integration of science and technology and finance, effectively increase financial support for scientific and technological innovation and entrepreneurship, accelerate the concentration of innovation resources to enterprises, improve the innovation ability of enterprises, and promote the deep integration of industry, university and research. The 10th China Innovation and Entrepreneurship Competition will be held from mid-October to early November 2021.
Kangyu Biology actively responded to the call of the state, in order to implement the major deployment of mass entrepreneurship and innovation proposed by the Party Central Committee and The State Council, carry forward the innovation and entrepreneurship culture, stimulate the enthusiasm of all employees for innovation, and set off a wave of innovation in the company. The company actively organized registration to participate in the innovation and entrepreneurship competition, and finally selected within the company, led by Wang Youwei, general manager of Kang Yu Xin Biology, a group of three people participated in the competition on behalf of the company.
Kang Yu Xin Biology in the competition and the participating companies compete on the same stage, the appearance of the "pyrazine drug intermediates kingdom" can be described as a five-pass, from the preliminary competition, industry competition, provincial final breakthrough, all the way into the national scientific and technological innovation "racetrack".
On October 13, the first national competition of the long-awaited 10th China Innovation and Entrepreneurship Competition - Biomedicine National Competition was held as scheduled in Hangzhou. The contestants of Kangyuxin are quick in thinking, and they displayed and promoted the entrepreneurial project within the specified time. Finally, they passed the face-to-face defense calmly and perfectly, fully demonstrating their serious attitude and superb level, and achieved excellent results with practical actions. A total of 33289 enterprises registered for the 10th China Innovation and Entrepreneurship Competition, including 4931 in the field of biomedicine, after 37 local events, layer by layer selection, 340 biomedicine fierce competition, Baiyinkang Yuxin Biotechnology Co., Ltd. with excellent results won the growth group "excellent Enterprise" award.
Autumn is the season of harvest. Kangyuxin actively responds to national policies, has been working in the field of biomedical intermediates industry for more than 10 years, and has achieved fruitful results in innovation and entrepreneurship. In particular, it has made considerable achievements in the synthesis of pyrazine compounds and has become the leader of the domestic pyrazine industry. Next, Kangyuxin will continue to take "innovation for development, pyrazine for the future" as its mission, and strive to make due contributions to the society as a scientific research enterprise
Kang Yu Xin biological
Kangyuxin Biotechnology Co., Ltd. was established in October 2013, specializing in the research and development, production, sales and related service technology development of pyrazine intermediates and process libraries. Kangyuxin has more than 2,000 square meters of standardized laboratories, with an output value of more than 80 million yuan in 2022. The core technology of pyrazine derivatives of Kangyuxin ranks the leading level in China, and the varieties and orders of pyrazine series products are ranked first in the domestic industry. Kangyuxin has an experienced and high-quality drug process research and development team, which can realize the research and development and process production from lead compounds to clinical batch apis. Kangyuxin Drug Quality research team can provide effective data and method validation for drug registration and research.
The company was supported by the innovation Fund of Gansu Province in 2016, and was identified as the first batch of provincial science and technology innovation enterprises by the Department of Science and Technology of Gansu Province, and has been supported by the science and technology innovation Fund of Lanzhou and Baiyin for many times. Wang Youwei, the founder of the company, was named "One hundred innovative and entrepreneurial models in Lanzhou City" in 2015. Kangyuxin, as the first domestic enterprise to develop a broad spectrum antiviral new drug "Fapiravir", was shortlisted in the eighth batch of key protection enterprises for epidemic prevention materials in Gansu Province. Kangyuxin won the Excellence Award of the 10th China Innovation and Entrepreneurship Competition National Biomedical Industry Competition in 2021 (the second place in the group), and the second place in the Gansu Division of the 10th China Innovation and Entrepreneurship Competition. Won the first prize in the Northwest region of the 2020 "Guotong Cup" Lanzhou University Global Alumni Entrepreneurship Competition, and the first prize of the Baiyin Double Innovation Competition for two consecutive years in 2020 and 2021. In 2022, it will be evaluated as a high-tech enterprise and a specialized and special new enterprise.
